Online / Physical Event

4th International Conference on

Biosimilars and Biologics

Theme: New Horizons in Biosimilars and Biologics

Event Date & Time

Event Location

London, UK

Brochure Program Abstract Registration ReaderBase Awards

20 Years Of Excellence in Scientific Events



Conference Speaker


CEO at MAIN (MaQasid Angel Investors Network)

Conference Speaker


The Scripps Research Institute, Florida United States

Conference Speaker


Shizuoka University, Japan Japan

Conference Speaker


MIGAL Galilee Technology Center -Tel Hai College, Israel Israel

Conference Speaker


CEO, ChemPass (Hungary) Hungary

Conference Speaker


UCL School of Pharmacy UK

Conference Speaker


Director Cell Line Development bij Bioceros BV Netherlands

Tracks & Key Topics

Biosimilars 2023



We take colossal delight to invite all the participants around the globe to join us at 4th International Conference on Biosimilars and Biologics taking place on October 02-03, 2023 at London, UK. The Biosimilars 2023 has turned in to a premier forum to network, learn and engage with professionals, academicians, scholars, researchers and activists in creating a platform to discuss and disseminate meaningful messages, values, and practices in the subject of Biosimilars and Biologics.

The scientific program includes Keynote & Plenary talks, Video Presentations, Poster Presentations, and E-Posters. Furthermore, oral communications of (post)doctoral junior scientists will be considered. It is the goal of the organizers to make this meeting an event of scientific excellence, attractive to both industrial and academic scientists and its advancements.

We invite sponsors and exhibitor to showcase your products to our participants and make it reach the public through them. We request you to make use of this opportunity to make the world a better place to live in.

EuroSciCon is the longest running independent life science events company with a predominantly academic client base. Our multi-professional and multi-specialty approach creates a unique experience that cannot be found with a specialist society or commercially.

Euroscicon are corporate members of the following organizations

  • Royal Society of Biology
  • IBMS
  • British Society for Immunology
  • Rare Care UK
  • Opportunities for Conference Attendees

For Researchers &Faculty:

For Universities, Associations & Societies:

For Students & Research Scholars:

  • Poster Competition (Winner will get Best Poster Award)
  • Young Researcher Forum (YRF Award to the best presenter)
  • Student Attendee
  • Group Registrations

For Business Delegates:

For Companies:

  • Exhibitor and Vendor Booths
  • Sponsorships opportunities
  • Product launch
  • Workshop organizing
  • Scientific Partnering
  • Marketing and Networking with clients

Euroscicon organizes International Biosimilars Meetings annually across Europe, Austria, Ireland, Germany, France, Liechtenstein, Lithuania, Finland, Luxembourg, Hungary, Italy, Norway, Poland, Denmark, Macedonia, Greece, Portugal, Romania, Czech Republic, Switzerland, United Kingdom, Belgium, Scotland, Latvia, Ukraine, Sweden, Denmark, Spain, Netherlands Russia, Bulgaria, France, with solitary subject of quickening logical revelations.

Conference Topics




Track 1: Current Challenges in Developing Biosimilars

The development of biologics calls for overcoming lot many challenges. As comparisons are being drawn from the initial stages, it is very important to have proper scientific as well as strategic approached taken for the successful development of these Biosimilars. The need for overcoming the challenges continues till the late clinical steps, drug safety factors and labelling requirements. Also it is much required now to develop a drug product in accordance to quality by design (QbD).

Track 2: Biosimilars in Therapeutics

Biosimilars Market is experiencing a growth at an exponential rate. With the effectiveness of biosimilars and its cheap price, biosimilars is in huge demand in the pharmaceutical market. With the advancement of Biosimilars, disease management has become comparatively easier.  It is currently being used in the treatment of ailments like psoriasis, rheumatic arthritis, cancers, inflammatory bowel disease(IBD) etc. Biosimilar insulin’s have already started revolutionizing the future drug development in the realm of diabetology.

Track 3: Clinical Trials of Biosimilars

As the demand of Biosimilars is ever increasing in the pharmaceutical market, it is very important to check them properly before releasing it to the mass. That is why there is a stepwise approach towards clinical trials of Biosimilars. It has various levels such as Extensive Molecular characterization Program, Pre-Clinical, Phase 1, Phase 3, Phase 4 and so on.

Track 4: Biosimilars in Oncology

Cancer is something which if treated properly is not hard to beat. Most of the medicines that we currently have for Cancer are way too costly for any common human being, but Cancer being one of the largest causes of death needs proper treatment. This is where Biosimilars come handy. Biosimilars being cheaper can increase access worldwide to potentially lifesaving biologics.

Track 5: Monoclonal Antibody Biosimilars

Monoclonal antibodies (mAbs) are natural specialists that are broadly used to treat malignancies including non-Hodgkin's lymphomas and ceaselesslymphocytic leukaemia. They are compelling however costly. The licenses for some, mAbs are lapsing, so Biosimilar solutions, which contain an adaptation of the dynamic element of the first medication, are being produced. The first mAb biosimilars to be approved in Europe and elsewhere was theinfliximab biosimilars (Inflectra and Remsima), which originator is Remicade.

Track 6: Drug Development and Delivery

Drug development is the process of bringing a new pharmaceutical drug to the market once the led component has been identified through the process of drug discovery. It further has pre-clinical and clinical development procedure. Once the drug has been developed, it is important to check its mode of function, this is termed as the drug delivery.  Once this has been done, the drug can be qualified for usage.

Track 7: Biopharmaceuticals

A biopharmaceutical is also known as abiologic or biological medical product. It is any pharmaceutical drug product which is manufactured in, extracted from, or semi synthesized from biological sources. They are different from totally synthesized pharmaceuticals. They include vaccines, blood and blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy.

Track 8: Biosimilars Pipeline

Biosimilars is a Biologic therapeutic item which is duplicate of a unique item that is made by an alternate organization. Biosimilars are formally affirmed creative adaptations of unique items, and can be made when the first item's patent terminates. Reference to the innovator product is an integral component of the approval.

Track 9: Biosimilar Switch

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the therapeutic management of inflammatory rheumatic diseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.

Track 10: Biological Products

Biological Products means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein or analogous product, or arsphenamine or derivative of arsphenamine, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

Track 11: Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has most extreme significance in setting to the way that lone an appropriately bioequivalent sedate competitor that adjusts the outcomes in all regards to the first authorized item can be called as Biosimilar tranquilize.

  • Strategies for the Bioequivalence Assessment of Topical Dosage Forms
  • Evaluation of Highly Variable Drugs and Drug Products
  • Bioequivalence Approaches for Transdermal Dosage Forms
  • Bioequivalence Assessment of Respiratory Dosage Form

Track 12: Challenges in Pharmacovigilance

This session of the Biosimilars 2020 will be looking into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in Pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilancepractice and pharmacoepidemiology.

  • Role of Pharma Industries in the Improvement of Pharmacovigilance System
  • Current Problems in Biosimilar Pharmacovigilance
  • Detection and Evaluation of Drug Safety Signals
  • Pharmacoepidemiology and GMP

Track 13: Intellectual Property Rights

The safeguarding of product trade secret, its formulations and other process parameters by law is usually covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance in the field of biologics and biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. The very name Biosimilars calls for the occurrence of Intellectual Property rights laws and by-laws. Hence this session is of utmost interest to the attorneys and law personnel.

Track 14: Regulatory Approach for Biosimilars

Biosimilars are the generic version of biological. It is the new buzz word in pharmaceutical industry. Biosimilars are highly similar to licensed reference product not withstanding minor differences in clinically inactive components; also there are no clinically meaningful differences between the biologicals and the reference product in terms of safety, purity, and potency.

Track 15: Globalization of Biosimilars

Globalization of Biosimilars tells us about the generic drugs impact on global biosimilars market, Cost and risk management, and Adopting innovative mechanisms such as risk-sharing arrangement, and European market for biosimilars. The global market scenario with the launch of first biosimilars in the market forecasts some radical changes. Globalization of Biosimilars will look upon such key concerns which are witnessed by the global pharma market and that are coming up with the subsequent launch of the other biosimilars and biologics.

Track 16: Biosimilars Development in Markets

A Biosimilars bio therapeutic item is comparative (but not identical) as far as quality, wellbeing, and viability to an effectively authorized reference item. Not at all like nonspecific little particles, it’s hard to institutionalize such naturally complex items in light of convoluted assembling forms. Biologics are among the most elevated cost medicines on the worldwide market today, which suggests the requirement for minimal effort choices. In developing markets, biosimilars officially offer more moderate costs, which are alluring, as well as crucial to economies where costly medications are not monetarily achievable.

Track 17: Chemical and Analytical Strategies for Biosimilars

Management of cGMP facility calls for a strict monitoring all factors including analytical strategies, formulation procedures, packaging etc. For biologic products establishing comparability and interchangeability is a big hurdle. For this purpose employment of suitable analytical approach, bioassay, protein analysis, potency testing, safety assurances are highly important. LC/MS analysis for biologic products, characterization of biologics, peptide mapping, Isoelectric Focusing and Capillary Isoelectric Focusing, SDS-PAGE, Thermal Analysis, Particulate Matter Analysis, Thermo gravimetric Analysis are some methods commonly used for analysis of biologics and Biosimilars products. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry.

Track 18: Biological Medicine

Biological Medicine works with the biology of the body and its natural healing capabilities as well as the spiritual, emotional and physical aspects of disease. Disease means that the body’s regulation is not working properly and needs to be brought back into its natural dynamic state where the immune system is in full regulation.  It therefore looks for root causes for the presenting symptoms of disease the underlying factors causing a person to present with a certain illness.  These root causes may consist of several factors which have built up over time and can include; diet, food allergies, intestinal disturbances, family history, stress, environmental factors, heavy metals, dental problems, hyperacidity, trauma, exposure to bacteria or viruses or electromagnetic disturbances.

Track 19: Clinical and translational biomarkers

Detection phases of clinical support and translated biomarkers are inclined to identify the effect of compound on organs or tissues before the clinical effect is exhibited. It is often classified into three general classes: biomarkers for disease, target biomarkers and Mechanism biomarkers. A biomarker for translation is predicated on whether it is often noticeable, quantifiable, and eventually it is often trained or verified.

Track 20: Cardiovascular Biomarkers

Cardiovascular disease (CVD) remains the foremost think about the world. The detection of traditional risk factors like age, hypertension, diabetes, and smoking enhanced the first prevention of CVD. Heart indicators are measured biomarkers to gauge heart function. They’re often examined within the context of myocardial infarct, but other circumstances can cause a rise within the level of the gut’s marker. Cardiac biomarkers are elements that release into the blood when the guts are wounded or stretched. A heart marker is employed to spot and stratify proliferation of patients with pain and presumed acute coronary syndrome (ACS). These markers include enzymes, hormones, and proteins. Cardiac biomarkers have appeared as an important tool in cardiology over the past fifty years, namely for primary and secondary prevention, diagnosis, and treatment of acute myocardial infarct (AMI), and diagnosis and stratification of the danger of coronary failure.

Track 21: Molecular Biomarkers

Molecular biomarkers defined as biomarkers which will be revealed through basic and widely accepted proposals like genomics and proteomics, sideways from genomics and proteomics platforms, biomarker assessment techniques like metabolomics, lipidomic, and glycemic are most usually used as biomarker recognition techniques. Molecular biomarkers are categorized into pathological biomarkers, macromolecule biomarkers, Insilco biomarkers, glycoprotein biomarkers and bio-imaging markers buoyed their structure and functioning. These biomarkers are often tested for non-abnormally composed biological fluids, like blood or serum.

Track 22: Biomarkers in drug Discovery

Drug finding with biomarkers is employed exclusively for diagnosis and monitoring of patients in clinical trials. Biological markers improve the success rates of drug advancement programs and thus hasten the supply of advanced therapies. Biomarker enhancement may be a multi-step and repetitive process starting with the invention of biomarkers in contagious diseases. During this session, an analytical authentication phase of biomarker development, pharmacogenomics, functional proteomics, biological analytical validation method, pharmacokinetic models are going to be created.

Track 23: Applications in Biomarkers

Bio markers are used as pinpointing tools for precisely identifying disease states, for identifying high-risk and predictable individuals, effectively treating patients with illnesses, and are targeted to specific biological sites. Advances in genomics, proteomics, metabolomics, and bioinformatics have made it possible to get several biomarkers

Track 24: Blood Biomarker

Blood biomarkers are engaged in MS (MS) studies, autoimmune dysfunction of the central system nervous. There’s a big needn't met by biomarkers to assess prediction, response to treatment or potential complications in treatment. There are several constraints within the process of finding and validating an honest biomarker, like the pathophysiological complexity of MS and therefore the technical difficulties of a worldwide standard of methods for selection, processing, and maintaining biological trials.

Track 25: Biomarkers & Research

Biomarkers are the particles which demonstrate ordinary/anomalous process occurring in the body and may be the indication of a hidden condition or sickness. Different kinds of atoms can fill in as biomarkers, for example, DNA (genes), proteins or hormones since they all demonstrate the status of your wellbeing. Biomarkers participate in different procedures like diagnosis and prognosis, expectation and estimation of treatment reaction, and security assessment. The atomic biomarkers are solely being created and approved to be utilized as a part of medication improvement and are utilized to help endorsement of medication items.

Track 26: Role of Biomarkers in Translational Science

In the post-genomic time, it has turned out to be obvious that hereditary changes alone are not adequate to see most sickness forms including tumor. Genome sequencing has uncovered an unpredictable arrangement of hereditary changes in disease, for example, point transformations, chromosomal misfortunes, quality intensifications and telomere shortening that drive harmful development through specific signaling pathways. Proteome-based methodologies are vital supplements to genomic information and give essential data of the objective driver particles and their post-translational changes. By applying quantitative mass spectrometry, this is an elective method to distinguish biomarkers for early diagnosis and personalized medicine.

Track 27: Biomarker Assay Validation & Patient Stratification

Biomarker inquire about is a consistent procedure starting with revelation and then continues to approval process till the usage of biomarkers in the clinical setting. Hopeful biomarkers which are distinguished in disclosure organize should be approved over the quantity of tests. The test is to build up a quick and focused on investigation strategy that is equipped for dissecting whatever number recognized competitors as would be prudent in least hundred and possibly even a huge number of tests. Biomarker competitors distinguished amid revelation process are approved utilizing bigger examples which covers a wide area of patients. The check organizes gives affirmation that a specific philosophy is reasonable to be utilized as a part of the validation stage.

Track 28: Biomarker Development - Omics Technologies

In recent years, the utilization of high-throughput omics advances has prompted the fast revelation of numerous hopeful biomarkers. Notwithstanding, few of them have made the progress to the facility. In this survey, the guarantee of omics advances to add to the procedure of biomarker improvement is depicted. A diagram of the present state around there is given cases of genomics, proteomics, transcriptomicsmetabolomics and micro bionics biomarkers in the field of oncology, alongside some proposed systems to quicken their approval and interpretation to enhance the care of patients with neoplasms. The inherent complexity underlying neoplasms joined with the prerequisite of growing all around planned biomarker disclosure forms in view of omics advancements introduce a test for the compelling improvement of biomarkers that might be helpful in managing treatments, tending to illness hazards, and anticipating clinical results.

Track 29: Biomarkers for non-invasive diagnostics

There is developing logical enthusiasm for the examination of metabolomics and quantities of studies have concentrated on the use of non-intrusive biomarkers in the determination.

Track 30: Biomarkers in Drug Discovery

Biomarkers of illness assume a critical part in prescription and have started to accept a more prominent part in medicate disclosure and advancement. The test for biomarkers is to permit prior, more powerful medication wellbeing and adequacy estimations. Their part in tranquilize advancement will keep on growing for years to come. For biomarkers to accept their legitimate part, more prominent comprehension of the instrument of ailment movement and helpful intercession is required. What's more, more noteworthy comprehension of the prerequisites for biomarker choice and approval, biomarker examines strategy approval and application, and clinical endpoint approval and application is required. Biomarkers should be considered while the remedial target is yet being distinguished and the idea is being defined.

Track 31: Biomarkers for Cancer Screenings

Screening for early invasive disease has the potential to reduce mortality from cancer. Because of their ease of measurement, several biomarkers have been evaluated or are currently undergoing evaluation as screening tests for early cancer. These include the use of biomarkers in screening for cancer in high-risk subjects. Although biomarkers have many attractive features as cancer screening tests, lack of sensitivity and specificity, when combined with the low prevalence of specific cancer types in asymptomatic subjects, limit their application for the early detection of cancer.

Track 32: Types of cancer biomarkers

There are numerous types of cancer biomarkers, and they each work contrastingly inside the body and respond diversely to medicines. In general, cancer biomarkers are grouped by their distinctive capacities. Tumor biomarkers can incorporate, proteins, gene transformations & changes, gene adjustments, extra duplicates of genes, missing genes and other molecules.

Track 33: Uses of biomarkers in various areas

Biomarkers give a dynamic and ground-breaking way to deal with understanding the range of neurological sickness with applications in observational and explanatory the study of disease transmission, randomized clinical trials, screening and diagnosis and prognosis. Characterized as adjustments in the constituents of tissues or body liquids, these markers offer the methods for homogeneous arrangement of a malady and hazard factors and the can expand our base data about the fundamental pathogenesis of ailment. Biomarkers can likewise mirror the whole range of malady from the soonest signs to the terminal stages.

Track 34: USFDA Approved Biosimilars

In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve Biosimilars to those biologics originally approved through the PHS Act pathway. Since 2004 the FDA has held a series of public meetings on Biosimilars. The FDA has previously approved biologic products using comparability, for example, Omnitrope in May 2006, but this like Enoxaparin was also to a reference product, Genotropin originally approved as a biologic drug under the FD&C Act.

Track 35: Formulation Strategies for Follow-on Biologics

For this rapidly growing industry sector, little consensus or authoritative information is available yet regarding how and where biosimilar products will be produced. The future of their manufacturing is still up in the air. Much discussion among experts has focused on a dramatic up-tick in Contract Manufacturing Organizations (CMOs) involvement with process development projects and clinical-scale manufacturing for biosimilars. None have really set up commercial-scale projects (yet), however. Many such companies are publicly discussing large-scale partnerships for production in India and elsewhere in Asia. On the other hand, some biosimilars sponsors are establishing relationships with smaller biotech CMOs that have demonstrated expertise in efficiency or lower-cost business models.

Track 36: Legal Issues and BPCI Act

The legal issues pertaining to the follow-on-biologics and biosimilars are one of the most aspects that require an open discussion. Before the actual advent of biosimilars to the market legal issues have risen in numbers in their developmental stages. Renowned organizations have filed cases against each other two claim their rights and for other legal allegations related to the products. This track is dedicated to discussion of all such cases which has been argued in the court of law.

By 2002, the FDA had approved 36 new biologics, followed by 37 more in 2003, another 40 in 2004 and 39 more in 2005. By 2006, the leading category of biologic treatment, the red blood cell enhancer recombinant erythropoietin (EPO), generated $14 billion in sales revenues, or 40 percent more than the best-selling traditional pharmaceutical, Lipitor. More than 300 therapeutic antibodies currently are in clinical development and trials, compared to just 13 that already are widely available due to legal issues.




The biosimilar market reached a value of US$ 13.0 Billion in 2021. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to reach US$ 60.8 Billion by 2027, exhibiting at a CAGR of 26.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

The biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. In 2018, the recombinant non-glycosylated proteins segment is expected to account for the largest share of the market. New product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are the factors driving the growth of this segment.

The biosimilars market is segmented into in-house manufacturing and contract manufacturing organizations. In 2018, the contract manufacturing segment is expected to account for the largest share of the market

The biosimilars market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period. The rising incidence of cancer, high cost of biologics, pressure to reduce healthcare expenditure, and low cost of biosimilars are factors contributing to the growth of this segment.

American Market: The USA is the largest market for biologics globally. With the approval of the first biosimilar in the U.S in early 2015 and the expected patent expiration of 12 biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market.

In 2010, patient care act was passed by Obama which gives licensure pathway for interchangeable products, which provided under the part of Biologics Price Competition and Innovation Act for the product demonstrating as biosimilar, manufacturers need to submit Biologics License Application (BLA). Target reference products for the USA market are Monoclonal Antibodies (MAbs), recombinant protein and some high-purity protein products, out of which recombinant therapeutic with the large market (sales) even with a small profitable amount.

Biosimilar market is expected to represent CAGR of 62.2 % as the chances of growth of biosimilar market from $1.7 billion in 2014 to $30 billion by 2020.

Biosimilars will account for 4% to 10% of the biologics market total by 2020, depending on the number of biosimilars launched in the U.S. The U.S. is the largest market for biologics and the biosimilars can achieve 10% of the global sales in 2020, only if the volume growth for biologics is achieved in the U.S. market.

.Biosimilar market in Europe:

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars in Europe. patent expiry of key product classes and a growing emphasis on cost-effectiveness are making governments switch to affordable alternatives.

The EMA approved four additional biosimilars in 2016, including three biosimilars in two new product classes: a biosimilar of Amgen’s Enbrel (etanercept) and two biosimilars of Sanofi’s Clexane (enoxaparin sodium).  Etanercept is a fusion protein used to treat a variety of autoimmune disorders and enoxaparin sodium is a low-molecular-weight heparin indicated for preventing blood clots.  These additional approvals bring the total of currently authorized biosimilars in Europe to 22 and the product classes to eight

It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity.

The biosimilars market in Asia Pacific: Asia-Pacific is the fastest growing market for biosimilars because of low manufacturing expenses, availability of skilled and cheap labor, lenient regulations laid by governments. In fact, governments are encouraging the use of biosimilars. For example, the government of India provides various necessary and regulatory procedures for the usage of biosimilars products.

Asia-Pacific Biosimilars Market was worth $0.78 billion in 2016 and estimated to be growing at a CAGR of 39%, to reach $4.05 billion by 2021.

Based on geography the Asia-Pacific market is segmented into various regions namely Japan, China, India and Australia.

India and China are estimated to grow the fastest. Other countries such as South Korea are also expected to record high growth over the next five years. India is one of the largest hubs for the biosimilar industry and observes a presence of over 30 leading firms that operate in the development of biosimilars, some of which include Dr. Reddy’s Laboratories, Wockhardt, Lupin, Cipla, Avesthagen, Biocon, and Zydus Cadilla.

Biosimilar market in the Middle East: The Middle East and Africa Biosimilars Market was worth $0.37 billion in 2016 and estimated to be growing at a CAGR of 32%, to reach $1.63 billion by 2021.

Biosimilars are rising as a standout amongst the most vital area in the medicinal services industry. With expanding social insurance costs, biosimilars are being looked upon as a moderate treatment alternative. Developing economies are watching far-reaching development in biosimilars industry from requesting clinical necessities of therapeutics. Ascend in GDP and human services consumptions, and the interest for practical therapeutics arrangement has brought about the development of this market.

Few Global Universities for Biosimilars:

  • University of California, USA
  • North Carolina State University, USA
  • University of London, UK
  • Biotechnology Information Institute, USA
  • University of Toronto, Canada
  • Biotechnology Information Institute, USA
  • USC Keck School of Medicine, USA
  • University of La Sabana, Colombia
  • University of Pannonia, USA
  • USC Keck School of Medicine, USA
  • Touro College of Pharmacy, USA

Global Societies and Associations for Biosimilars in the USA:

  • The Biosimilars Council
  • Association for Accessible Medicines
  • Biosimilars Resource Center (BRC)
  • American Academy of Nanomedicine
  • American Nano Society
  • American Society for Nanomedicine

Global Societies and Associations in Asia:

  • National Center for Nanoscience and Technology
  • Indian Society for Nanomedicine
  • Nano Technology Research Association
  • Indian Society of Nanomedicine

Global Societies and Associations in Europe:

  • Medicines for Europe
  • British Biosimilars Association (BBA)
  • Europian Medicines Agency
  • European Association of Hospital Pharmacists
  • International generic and biosimilar medicines association (IGBA)
  • Nanotechnology Industries Association
  • Royal Microscopical Society
  • Royal Society - Nanotechnology and Nanoscience
  • British Society for Nanomedicine

Biomarkers Market Analysis:

In 2019, the global biomarkers market size was valued at USD 46.3 billion and is anticipated to expand at a CAGR of 13.7% over the predicted period. High ubiquity of cancer is encouraging research initiatives, driving the growth of the market. Technological advancements and extensive research used for the development of biomarker-based clinical diagnostics are expected to be the key contributors for market. A rising number of Contract Research Organizations (CROs) is expected to further fuel the demand.

In 2020, the market size of global biobanks was estimated at USD 65.9 billion and is anticipated to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. High investments for R&D of advanced therapies such as personalized medicine, regenerative medicine, and cancer genomic studies are driving the space. Moreover, the onset of COVID-19 has put bio banks at the cutting edge of pandemic control measures, resulting in the organic revenue growth of the market. In 2019, the global biomarkers market size was valued at USD 46.3 billion and is anticipated to expand at a CAGR of 13.7% over the predicted period. High ubiquity of cancer is encouraging research initiatives, driving the growth of the market. Technological advancements and extensive research used for the development of biomarker-based clinical diagnostics are expected to be the key contributors for market. A rising number of Contract Research Organizations (CROs) is expected to further fuel the demand.

In 2020, the market size of global biobanks was estimated at USD 65.9 billion and is anticipated to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. High investments for R&D of advanced therapies such as personalized medicine, regenerative medicine, and cancer genomic studies are driving the space. Moreover, the onset of COVID-19 has put bio banks at the cutting edge of pandemic control measures, resulting in the organic revenue growth of the market.


Benefits of Attending

Participants can acquire direct admittance to experts and chiefs and can build perceivability through marking and systems administration at the gathering.

Learn and talk about key news and difficulties with senior level speakers.

With introductions, board conversations, roundtable conversations, and workshops, we cover each point start to finish, from worldwide large scale issues to techniques to strategic issues.

Discuss quality activities that can be applied in the training.

Discuss approaches to work together in setting up quality activities all through the Biosimilars, Biologics and Biomarkers.

Exchange thoughts and organization with driving Surgeons, Physicians, Doctors, Nurses, Health policymakers, Health experts, Engineers, Researchers from in excess of 40 nations.

Get affirmed for your interest.

Knock Down Geographical Barriers.

Great asset for acquiring new vocation abilities.

Learn from the Pros.

Global openness to your examination.


Examination Contribution and Achievement

Expert Level (Scientific Service Achievement Award)

Professional Level (The Research Contribution Award)

Scholar Level (The Upcoming Researcher Award)

Women Scientist (The Women of Science Award)

Outstanding speaker in Biosimilars 2023

Best Keynote Speaker in Biosimilars 2023

Best Poster Presentation in Biosimilars 2023

Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation in Biosimilars 2023


Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!